Novo Nordisk A/S $NVO Shares Acquired by Fiduciary Alliance LLC

Key Points

• Fiduciary Alliance LLC significantly increased its holdings in Novo Nordisk A/S by 473.0% during the 2nd quarter, now owning 46,927 shares worth approximately $3.24 million.
• Novo Nordisk reported $0.97 earnings per share for the last quarter, surpassing expectations, with a strong return on equity of 78.64% and a net margin of 35.60%.
• The company recently announced a semi-annual dividend with a yield of 240.0%, which was paid out on August 26th, 2023.

Fiduciary Alliance LLC lifted its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 473.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 46,927 shares of the company's stock after buying an additional 38,737 shares during the period. Fiduciary Alliance LLC's holdings in Novo Nordisk A/S were worth $3,239,000 at the end of the most recent reporting period.

Other institutional investors also recently added to or reduced their stakes in the company. Copeland Capital Management LLC raised its position in shares of Novo Nordisk A/S by 184.8% during the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock worth $27,000 after buying an additional 255 shares in the last quarter. North Capital Inc. acquired a new position in shares of Novo Nordisk A/S during the first quarter valued at approximately $27,000. Park Square Financial Group LLC bought a new stake in Novo Nordisk A/S during the fourth quarter worth approximately $29,000. Stone House Investment Management LLC acquired a new stake in Novo Nordisk A/S in the first quarter worth approximately $30,000. Finally, Disciplina Capital Management LLC boosted its stake in Novo Nordisk A/S by 162.3% during the 1st quarter. Disciplina Capital Management LLC now owns 480 shares of the company's stock valued at $33,000 after purchasing an additional 297 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company's stock.

Novo Nordisk A/S Trading Up 1.4%

NYSE:NVO opened at $55.62 on Tuesday. The company's 50 day moving average is $57.69 and its 200-day moving average is $65.92. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. Novo Nordisk A/S has a 12 month low of $45.05 and a 12 month high of $138.22. The firm has a market cap of $248.34 billion, a price-to-earnings ratio of 15.28, a P/E/G ratio of 2.08 and a beta of 0.66.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported $0.97 earnings per share for the quarter, topping the consensus estimate of $0.93 by $0.04. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%.The business had revenue of $11.69 billion during the quarter, compared to analysts' expectations of $77.51 billion. Equities analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The business also recently announced a semi-annual dividend, which was paid on Tuesday, August 26th. Investors of record on Monday, August 18th were given a dividend of $0.4119 per share. The ex-dividend date of this dividend was Monday, August 18th. This represents a yield of 240.0%. Novo Nordisk A/S's payout ratio is 22.53%.

Analysts Set New Price Targets

NVO has been the topic of a number of research reports. TD Cowen dropped their price objective on Novo Nordisk A/S from $105.00 to $70.00 and set a "buy" rating on the stock in a research note on Tuesday, August 19th. Hsbc Global Res downgraded shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 31st. UBS Group lowered shares of Novo Nordisk A/S from a "buy" rating to a "neutral" rating in a research report on Tuesday, August 5th. Wall Street Zen cut shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Saturday, August 2nd. Finally, Sanford C. Bernstein raised shares of Novo Nordisk A/S from a "market perform" rating to an "outperform" rating in a research note on Tuesday, September 9th. Four investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Novo Nordisk A/S presently has an average rating of "Hold" and an average price target of $81.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.